
|Articles|November 20, 2017
Quanticate Launches Monitoring Services Following the ICH GCP E6(R2) Addendum
Advertisement
Quanticate has launched its statistical monitoring service as an extension of its consultancy offering in response to recent amendments to the ICH GCP E6(R2) guidelines which focus on incorporating RBM into trial design. Quanticate will use the RBM approach a long with the evaluation of these designs to conduct tests in order to guide decisions surrounding investigations into data discrepancies and identifying where site directed monitoring visits may be necessary.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose
2
Precision Oncology Trials Need to Reflect the Complexity of Cancer Biology
3
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
4
ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor
5




